ClearPoint Neuro, Inc. filed a current report on Form 8-K on November 18, 2026, disclosing an amendment to its existing at-the-market equity offering sales agreement with Stifel, Nicolaus & Company, Incorporated, increasing the maximum aggregate sales proceeds available under the program from $50,000,000 to $150,000,000.
Key Highlights
- Program ceiling raised: The amendment increases allowable aggregate sales proceeds under the ATM program from $50,000,000 to $150,000,000, inclusive of prior sales.
- Shares already sold: As of the filing date, the company has sold approximately $22.5 million of common stock under the original sales agreement.
- Remaining capacity under current prospectus supplement: Approximately $27.5 million remains available for offer and sale under the existing ATM Prospectus Supplement dated November 7, 2024.
- Agent commission: The company has agreed to pay Stifel, Nicolaus & Company, Incorporated a commission of up to 3.0% of the gross sales price of shares sold.
- No obligation to sell: According to the filing, the company "is not obligated to sell any Shares under the Sales Agreement and may at any time suspend solicitation and offers."
- Termination flexibility: Either party may terminate the Sales Agreement at any time by giving written notice, and the agreement terminates automatically upon the issuance and sale of all shares.
ClearPoint Neuro Amends ATM Sales Agreement with Stifel on November 18, 2026
According to the filing, ClearPoint Neuro, Inc. (NASDAQ:CLPT) originally entered into its At-The-Market Equity Offering Sales Agreement with Stifel, Nicolaus & Company, Incorporated in November 2024, establishing a program with aggregate sales proceeds of up to $50 million. On November 18, 2026, the company and the agent executed an amendment to that agreement, raising the total ceiling to $150,000,000. The company disclosed that the $150,000,000 figure is "inclusive of the aggregate sales proceeds from sales of shares of the Company's common stock under the Original Sales Agreement."
The filing states that as of the report date, approximately $22.5 million in shares has been sold under the original agreement, leaving approximately $27.5 million available under the existing ATM Prospectus Supplement dated November 7, 2024. The company noted that the amount available under that prospectus supplement is not being increased by the amendment; if the company wishes to offer shares beyond the approximately $27.5 million still available under it, the company will file a new prospectus supplement to its existing Form S-3 registration statement (File No. 333-275476), which the SEC declared effective on November 20, 2023.
Under the terms described in the filing, the agent will use "commercially reasonable efforts" to sell shares from time to time based on the company's instructions, using any method defined as an at-the-market offering under Rule 415(a)(4) of the Securities Act. In addition to the commission of up to 3.0% of gross sales proceeds, the company agreed to reimburse the agent for certain specified expenses and to provide customary indemnification and contribution rights. The Sales Agreement Amendment was filed as Exhibit 1.1 to the report and was signed on behalf of the company by Chief Financial Officer Danilo D'Alessandro.
What Was Disclosed
ClearPoint Neuro disclosed an amendment to its ATM equity sales agreement with Stifel, Nicolaus & Company, Incorporated, expanding the program's total aggregate sales proceeds limit from $50,000,000 to $150,000,000, with approximately $22.5 million already sold and approximately $27.5 million currently available under the existing prospectus supplement.




Please wait processing your request...